Keynote 564 trial#

There are signs as well that the drug may improve survival rates, but we can't be sure of that for another few years.

Keynote 564 trial#

'This early data from the trial is very promising, with a clear reduction in the disease recurring in patients on pembrolizumab. The estimated 2-year OS rates are 96.6% for pembrolizumab and 93.5% for placebo. 0164) however, this has not cross the prespecified boundary of statistical significance. The median OS has not yet been reached in either arm but is trending favorably toward the PD-1 inhibitor (HR, 0.54 P =. The OS data are immature, with 3.6% (n = 18) and 6.6% (n = 33) events occurring in the pembrolizumab and placebo arms, respectively. 1 Per investigator assessment, the median disease-free survival (DFS) was not yet reached in either the pembrolizumab arm (n = 496) or the placebo arm (n = 498). Results shared in a webinar during the EAU meeting showed that at a median follow-up of approximately 24 months, adjuvant pembrolizumab induced a 32% reduction in the risk of disease recurrence or death compared with placebo (HR, 0.68 P =. Data from the phase 3 KEYNOTE-564 trial shared during the 2021 European Association of Urology (EAU) Congress showcased adjuvant pembrolizumab (Keytruda) as a potential new standard in renal cell carcinoma (RCC) however, investigators are still awaiting overall survival (OS) data to cement this role for the PD-1 inhibitor in the kidney cancer armamentarium.